KALA - Kala Pharmaceuticals Inc Stock Price, Fair Value and News

6.30USD+0.12 (+1.94%)Market Closed

Market Summary

USD6.30+0.12

Market Closed

1.94%

KALA Stock Price

View Fullscreen

KALA RSI Chart

KALA Valuation

Market Cap

17.7M

Price/Earnings (Trailing)

-0.42

Price/Sales (Trailing)

3.68

Price/Free Cashflow

-0.64

KALA Price/Sales (Trailing)

KALA Profitability

Return on Equity

-562.35%

Return on Assets

-75.42%

Free Cashflow Yield

-157.39%

KALA Fundamentals

KALA Revenue

Revenue (TTM)

4.8M

KALA Earnings

Earnings (TTM)

-42.2M

Earnings Growth (Yr)

32.83%

Earnings Growth (Qtr)

0.88%

Breaking Down KALA Revenue

Last 7 days

-4.4%

Last 30 days

-19.7%

Last 90 days

-11.5%

Trailing 12 Months

-59.1%

How does KALA drawdown profile look like?

KALA Financial Health

Current Ratio

6.33

Debt/Equity

4.56

Debt/Cashflow

-0.82

KALA Investor Care

Shares Dilution (1Y)

21.96%

Diluted EPS (TTM)

-17.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	4.8M
2022	9.3M	8.4M	5.7M	3.9M
2021	8.6M	10.8M	11.6M	11.2M
2020	5.8M	4.5M	5.3M	6.4M
2019	0	0	0	6.1M
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kala Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 04, 2024	iwicki mark t	sold	-30,547	6.73	-4,539	chief executive officer
Jan 04, 2024	reumuth mary	sold	-8,269	6.74	-1,227	chief financial officer
Jan 04, 2024	brazzell romulus k	sold	-10,898	6.74	-1,617	see remarks
Jan 04, 2024	iwicki mark t	acquired	-	-	14,300	chief executive officer
Jan 04, 2024	bazemore todd	acquired	-	-	6,500	see remarks
Jan 04, 2024	kharabi darius	sold	-9,321	6.73	-1,385	chief business officer
Jan 04, 2024	kharabi darius	acquired	-	-	4,600	chief business officer
Jan 04, 2024	bazemore todd	sold	-9,469	6.74	-1,405	see remarks
Jan 04, 2024	trachtenberg eric	acquired	-	-	4,600	see remarks
Jan 04, 2024	trachtenberg eric	sold	-8,269	6.74	-1,227	see remarks

Which funds bought or sold KALA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 10, 2024	Banque Cantonale Vaudoise	unchanged	-	-	6,000	-%
Apr 05, 2024	CWM, LLC	unchanged	-	1,000	2,000	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.34	-45,194	196,245	-%
Feb 14, 2024	Royal Bank of Canada	added	350	-	-	-%
Feb 14, 2024	BAKER BROS. ADVISORS LP	unchanged	-	-506,565	1,866,290	0.02%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-1.25	-267,033	928,718	-%
Feb 14, 2024	Board of Trustees of The Leland Stanford Junior University	unchanged	-	-40,141	147,889	0.01%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	added	2,149	17,085	18,109	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-6.00	21.00	-%
Feb 13, 2024	MORGAN STANLEY	reduced	-1.94	-3,358	11,354	-%

Are Funds Buying or Selling KALA?

Are funds buying KALA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KALA

No. of Funds

Unveiling Kala Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	millennium management llc	5.0%	135,096	SC 13G
Feb 14, 2024	checkpoint capital l.p.	0%	0	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	9.99%	269,213	SC 13G/A
Jan 29, 2024	integrated core strategies (us) llc	4.9%	130,704	SC 13G/A
Oct 18, 2023	longitude capital partners ii, llc	2.3%	57,541	SC 13D/A
Jun 15, 2023	checkpoint capital l.p.	9.7%	228,032	SC 13G
Feb 14, 2023	longitude capital partners ii, llc	3.4%	57,541	SC 13D/A
Feb 14, 2023	baker bros. advisors lp	9.99%	180,913	SC 13G
Jan 17, 2023	integrated core strategies (us) llc	6.7%	107,200	SC 13G
Jun 03, 2022	ra capital management, l.p.	4.7%	3,412,868	SC 13D/A

Recent SEC filings of Kala Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	PRE 14A	PRE 14A
Mar 29, 2024	S-8	Employee Benefits Plan
Mar 29, 2024	8-K	Current Report
Mar 29, 2024	424B5	Prospectus Filed
Mar 29, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 04, 2024	8-K	Current Report
Feb 16, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Kala Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Kala Pharmaceuticals Inc News

Latest updates

Kala Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2015Q4
Revenue	-	-	-	420	2,100	1,372	1,856	3,067	3,051	3,266	2,238	2,220	833	1,071	1,180	1,451	2,057	1,386	-
Operating Expenses	-6.2%	9,619	10,251	14,989	28,072	32,286	48,671	29,138	32,096	31,580	31,222	28,062	22,113	21,196	21,377	23,018	24,467	25,436	-
S&GA Expenses	-20.7%	4,623	5,831	9,549	22,673	26,982	24,027	25,349	27,986	27,699	26,466	23,893	15,301	15,408	14,492	15,280	17,007	18,236	-
R&D Expenses	-	-	-	5,391	4,473	4,466	-	2,881	3,094	3,126	3,397	3,468	6,053	5,434	6,138	7,070	7,108	6,959	-
Interest Expenses	-6.9%	1,468	1,577	1,447	2,207	2,035	2,076	2,072	2,091	2,141	2,170	2,157	2,134	2,128	2,113	2,180	2,125	2,094	-
Net Income	32.8%	-8,627	-12,843	29,073	-28,111	-32,941	-47,568	-28,127	-36,498	-30,412	-31,112	-27,948	-23,312	-21,955	-21,958	-23,176	-23,825	-25,388	-
Net Income Margin	24.1%	-8.75*	-11.52*	-13.84*	-16.29*	-15.53*	-12.69*	-10.85*	-11.69*	-13.18*	-16.40*	-	-	-	-	-	-	-	-
Free Cashflow	46.1%	-7,696	-14,279	-16,209	-25,963	-24,633	-28,448	-26,627	-22,152	-33,184	-26,463	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.5%	56.00	61.00	67.00	72.00	87.00	86.00	85.00	112	139	194	215	230	222	225	246	259	154	161	179	197	221
Current Assets	-8.7%	53.00	58.00	66.00	71.00	86.00	85.00	84.00	98.00	124	149	172	179	171	178	197	210	105	112	133	150	177
Cash Equivalents	-9.2%	51.00	56.00	49.00	64.00	70.00	52.00	43.00	65.00	92.00	125	145	128	77.00	46.00	128	196	85.00	98.00	118	139	171
Inventory	-	-	-	-	-	-	-	0.00	11.00	9.00	8.00	8.00	8.00	5.00	8.00	6.00	5.00	5.00	-	8.00	5.00	4.00
Net PPE	-6.1%	1.00	1.00	1.00	1.00	0.00	1.00	1.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00
Liabilities	-2.9%	48.00	50.00	49.00	49.00	68.00	87.00	117	117	123	132	131	120	122	119	117	117	125	118	118	115	116
Current Liabilities	-19.0%	8.00	10.00	10.00	10.00	26.00	40.00	33.00	33.00	37.00	27.00	26.00	20.00	22.00	20.00	17.00	17.00	25.00	18.00	18.00	15.00	17.00
Long Term Debt	0.9%	34.00	34.00	34.00	33.00	38.00	43.00	80.00	79.00	79.00	78.00	78.00	73.00	72.00	72.00	72.00	71.00	71.00	71.00	71.00	70.00	71.00
LT Debt, Current	-	-	-	-	-	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.9%	34.00	34.00	34.00	33.00	38.00	43.00	80.00	79.00	79.00	78.00	78.00	73.00	72.00	72.00	72.00	71.00	71.00	71.00	71.00	70.00	71.00
Shareholder's Equity	-33.1%	8.00	11.00	17.00	23.00	19.00	-	-	-	17.00	61.00	84.00	110	100	106	129	142	30.00	43.00	61.00	82.00	105
Retained Earnings	-1.4%	-629	-620	-612	-601	-587	-574	-603	-575	-542	-494	-466	-430	-399	-368	-340	-317	-295	-273	-250	-226	-201
Additional Paid-In Capital	0.8%	637	632	630	625	606	573	572	570	559	556	551	540	500	475	470	459	325	317	311	309	306
Shares Outstanding	2.5%	3.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	34.00	-	-	-	20.00	-	-	-	254	-	-	-	412	-	-	-	160	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-160.7%	-7,696	-2,952	-7,595	-9,684	-13,735	-15,665	-25,419	-24,089	-27,904	-26,083	-21,608	-32,640	-25,919	-25,641	-19,254	-19,880	-18,212	-22,912	-20,426	-31,170	-15,989
Share Based Compensation	-1.2%	2,374	2,403	1,362	1,324	960	1,327	1,916	2,805	2,748	3,928	4,710	4,702	4,063	3,978	2,774	2,497	2,325	2,572	2,621	2,473	2,198
Cashflow From Investing	-100.1%	-7.00	9,719	-10,033	-108	51.00	64,911	2,828	-5,073	-4,623	4,721	22,674	48,031	36,842	-57,601	-57,158	-292	-188	-204	-499	-444	-910
Cashflow From Financing	6237.5%	2,535	40.00	3,073	2,858	31,786	-39,872	-10.00	154	160	1,230	5,849	35,315	20,722	746	7,979	131,181	6,295	2,668	-10.00	29.00	122,915

KALA Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Product revenues, net	$ 0	$ 3,892
Costs and expenses:
Cost of product revenues		2,560
Selling, general and administrative	20,567	65,035
Research and development	18,586	17,653
(Gain) loss on fair value remeasurement of deferred purchase consideration	(230)	638
Loss (gain) on fair value remeasurement of contingent consideration	740	(288)
Total costs and expenses	39,663	85,598
Loss from operations	(39,663)	(81,706)
Other income (expense):
Interest income	2,711	664
Interest expense	(5,814)	(7,266)
Grant income	4,825
Loss on extinguishment of debt		(2,583)
Gain on sale of commercial business		46,995
Other (expense) income, net	(4,258)	(926)
Total other (expense) income	(2,536)	36,884
Net loss	$ (42,199)	$ (44,822)
Net loss per share attributable to common stockholders-basic (in dollar per share)	$ (17.35)	$ (29.48)
Net loss per share attributable to common stockholders-diluted (in dollar per share)	$ (17.35)	$ (29.48)
Weighted average shares outstanding-basic (in shares)	2,432,008	1,520,611
Weighted average common shares outstanding -diluted (in shares)	2,432,008	1,520,611
Statement of Comprehensive Loss
Net loss	$ (42,199)	$ (44,822)
Other comprehensive income:
Total comprehensive loss	$ (42,199)	$ (44,822)

KALA Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 50,895	$ 70,495
Prepaid expenses and other current assets (Note 7)	1,975	7,852
Current assets held for sale (Note 4)	0	7,595
Total current assets	52,870	85,942
Non-current assets:
Property and equipment, net	753	400
Right-of-use assets	2,025	16
Restricted cash and other long-term assets	301	462
Total assets	55,949	86,820
Current liabilities:
Accounts payable	919	2,832
Accrued expenses and other current liabilities	6,018	8,910
Deferred gain on sale of commercial business		4,189
Deferred grant income	1,075
Current portion of lease liabilities	334	13
Current portion of long-term debt		5,000
Current portion of contingent consideration		4,146
Current portion of deferred purchase consideration		595
Total current liabilities	8,346	25,685
Long-term liabilities:
Long-term lease liabilities	1,799
Long-term debt	34,190	37,937
Long-term contingent consideration	4,110	4,224
Total long-term liabilities	40,099	42,161
Total liabilities	48,445	67,846
Commitments and Contingencies (Note 17)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of December 31, 2023 and 2022; 51,246 and 53,144 shares of Series E Convertible Non-Redeemable Preferred Stock issued and outstanding as of December 31, 2023 and 2022, respectively, and 2,928 and 0 shares of Series F Convertible Non-Redeemable Preferred Stock issued and outstanding as of December 31, 2023 and 2022, respectively
Common stock, $0.001 par value; 120,000,000 shares authorized as of December 31, 2023 and 2022; 2,759,372 and 1,706,971 shares issued and outstanding as of December 31, 2023 and 2022, respectively	3	2
Additional paid-in capital	636,910	606,182
Accumulated deficit	(629,409)	(587,210)
Total stockholders' equity	7,504	18,974
Total liabilities and stockholders' equity	$ 55,949	$ 86,820

About Kala Pharmaceuticals Inc

KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

CEO	Mr. Mark T. Iwicki
WEBSITE	kalarx.com
INDUSTRY	Biotechnology
EMPLOYEES	34

Kala Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Kala Pharmaceuticals Inc? What does KALA stand for in stocks?

KALA is the stock ticker symbol of Kala Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kala Pharmaceuticals Inc (KALA)?

As of Fri Apr 26 2024, market cap of Kala Pharmaceuticals Inc is 17.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KALA stock?

You can check KALA's fair value in chart for subscribers.

What is the fair value of KALA stock?

You can check KALA's fair value in chart for subscribers. The fair value of Kala Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kala Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KALA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kala Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether KALA is over valued or under valued. Whether Kala Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Kala Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KALA.

What is Kala Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, KALA's PE ratio (Price to Earnings) is -0.42 and Price to Sales (PS) ratio is 3.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KALA PE ratio will change depending on the future growth rate expectations of investors.